Infuseon Therapeutics and OncoSynergy are teaming up to evaluate the latter’s monoclonal pan-CD29 antibody OS2966, delivered using Infuseon’s Cleveland Multiport Catheter™ (CMC), for the potential treatment of glioblastoma. The firms’ strategic alliance aims to establish proof of concept that OS2966 can be delivered directly to the brain using the CMC, prior to considering a Phase I study for the glioblastoma indication.

OncoSynergy is a University of California, San Francisco (UCSF) spin-out founded in 2011 to develop anticancer resistance mechanism inhibitors (RMIs). Lead candidate OS2966 is a first-in-class humanized, deimmunized antibody, which the firm says exhibits multiple mechanisms of action and has demonstrated significant efficacy in multiple models of aggressive and metastatic solid tumor types. OS2966 has been granted orphan drug designation by the FDA for the treatment of glioblastoma and ovarian cancer. OncoSynergy is headquartered at Johnson & Johnson Innovation’s JLABS incubator in South San Francisco.

“We are pleased to join forces with Infuseon Therapeutics to tackle the complex biology of glioblastoma,” commented Anne-Marie Carbonell, M.D., vp of clinical development at OncoSynergy. “The innovative combination of OS2966 and the CMC device seeks to address a huge unmet need and potentially change the way we treat patients suffering from malignant brain tumors.”

Infuseon was founded in 2012 to develop the multiport convection-enhanced CMC delivery device for the delivery of drugs directly into brain tissue.  Originally developed by Michael Vogelbaum, M.D., Ph.D., at Cleveland Clinic’s Brain Tumor and NeuroOncology Center and department of neurosurgery, the device was granted FDA 510(k) clearance earlier this year. 

 








This site uses Akismet to reduce spam. Learn how your comment data is processed.